Cardiac toxicities are associated with many types of cancer therapies, with both length of and time since treatment increasing a patient’s risk for the adverse event. Anthracycline chemotherapies are among the oldest agents still used for a variety of cancer diagnoses, and as cancer survivorship continues to grow, more patients are presenting with late-onset cardiac complications.

On July 9, 2021, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro^®) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor.

May annually marks a celebration of oncology nurses, and during its May 25, 2021, meeting, the ONS Board of Directors did just that: it welcomed and celebrated new members Valerie Burger, RN, MA, MS, OCN®, CPN, Danya Garner, MSN, RN, OCN®, CCRN-K, NPD-BC, and Patricia Geddie, PhD, APRN, AOCNS®, FCNS, and conducted an ice breaker to learn more about each other. Highlights from the decisions, updates, and other Board actions from that meeting follow.

On July 9, 2021, the U.S. Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv ([EV], Padcev®), a Nectin-4–directed antibody and microtubule inhibitor conjugate, for adult patients with locally advanced or metastatic urothelial cancer who previously received a programmed death receptor-1 (PD-1) or programmed death-ligand (PD-L1) inhibitor and platinum-containing chemotherapy or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.

Those without healthcare coverage can now purchase annual policies through state exchanges until August 15, 2021, under the Centers for Medicare and Medicaid Services’ (CMS’s) extended Special Enrollment Period (SEP), ensuring continued access to affordable coverage for Americans during a time of healthcare uncertainty.

Historically, ovarian cancer is often diagnosed at advanced stages because of vague symptoms and presentation, but with new advancements in diagnosis and treatment options, patients with the disease are living longer than ever.

In a bipartisan effort that recognizes patients' concerns about telehealth’s accessibility, the U.S. Senate promoted legislation to reduce barriers to care. Senators Brian Schatz (D-HI), Roger Wicker (R-MS), Ben Cardin (D-MD), John Thune (R-SD), Mark Warner (D-VA), and Cindy Hyde-Smith (R-MS), along with 50 colleagues, introduced the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021.

Companies marketing the tobacco brands Aspire, Joyetech, Vaporesso, and Voopoo, which were selected through a systematic process, must share information about social media marketing campaigns that target youth, the U.S. Food and Drug Administration (FDA) announced. The requirements include social media advertising documents and marketing plans, such as planned content to target specific audiences, cost of plans, use of partners and influences, and the number of followers and views broken down by age group.

MUTYH-associated polyposis (MAP) is an autosomal recessive hereditary cancer syndrome. It’s most commonly seen in people of northern European ancestry, where an estimated 1 in 20,000–40,000 have MAP (two pathogenic variants on opposite chromosomes) and 1%–2% have one MUTYH pathogenic variant.

African Americans have a higher cancer burden and face greater obstacles to cancer prevention, detection, treatment, and survival, according to the American Cancer Society. Health organizations such as ONS and the U.S. Food and Drug Administration (FDA) are dedicated to breaking down barriers and improve access to quality care and resources for those patients. To increase cancer awareness in one of the most vulnerable segments of the U.S. population, the FDA’s Oncology Center of Excellence (OCE) dedicated June 17–23, 2021, as National Black Family Cancer Awareness Week.